Central nervous system tumours are the most common solid tumours during childhood. Central nervous system primitive neuroectodermal tumours (CNS PNETs) are high-grade embryonal tumours that occur at any extracerebellar site in the CNS and are composed of undifferentiated or poorly differentiated neuroepithelial cells ([@bib35]). Currently, outcome for children with CNS PNET is poor with a 5-year survival rate of 31--53% ([@bib54]; [@bib16]). Pineoblastomas are highly malignant PNETs of the pineal gland, which histologically resemble other PNETs of the CNS ([@bib35]). In the United Kingdom, pineoblastomas are treated with protocols similar to CNS PNETs ([@bib51]).

Relatively little research has been undertaken to elucidate the molecular basis of CNS PNETs. Previously they have been grouped with the histologically similar tumour medulloblastoma; both being composed of poorly differentiated round 'small blue\' cells with scant cytoplasm ([@bib35]). Currently, CNS PNETS are treated with therapy designed for high-risk medulloblastoma ([@bib31]). However, several studies suggest this approach is less effective in CNS PNET than medulloblastoma ([@bib44]; [@bib54]; [@bib21]). Recent research has suggested there are molecular and genetic differences between CNS PNET and medulloblastoma ([@bib52]; [@bib23]; [@bib36]; [@bib47]).

An increased understanding of the molecular genetic basis of CNS PNET is therefore needed and will allow a more targeted approach to therapy. Recent research has started to elucidate the biological and genetic characteristics of CNS PNET and identify molecular subgroups ([@bib39]; [@bib49]). We previously published a study showing approximately one-third of supratentorially located CNS PNETs displayed WNT/*β*-catenin pathway activation, which was potentially associated with a better prognosis ([@bib58]). The WNT/*β*-catenin pathway has been found to be aberrantly activated in a number of cancers including medulloblastoma ([@bib13]; [@bib61]; [@bib28]; [@bib43]). The pathway has a role in many cellular functions including proliferation, differentiation and migration. When the pathway is inactive, the downstream effector *β*-catenin is bound to a cytoplasmic complex, which phosphorylates it targeting the protein for degradation. When a WNT ligand binds to its receptor the pathway is activated leading to the destabilisation of the cytoplasmic complex, preventing phosphorylation of *β*-catenin and allowing translocation to the nucleus where it acts as a transcriptional co-activator ([@bib41]).

In this study, we aimed to confirm the link between WNT/*β*-catenin pathway activation and prognosis in supratentorially located CNS PNET and additionally investigate the biological effects of pathway activation. We have extended our cohort of supratentorially located CNS PNETs analysed for WNT/*β*-catenin pathway status using *β*-catenin immunohistochemistry (IHC), through which we demonstrated a significant link with a better survival. In addition, we utilised previously published genomic copy number and mRNA expression array data to identify a molecular profile linked to CNS PNETs with WNT/*β*-catenin pathway activation ([@bib30]; [@bib39]). Genes involved in development of the CNS were identified suggesting this process may be disrupted in the tumours through aberrant pathway activation. Central nervous system primitive neuroectodermal tumours with pathway activation displayed lower levels of markers of neuronal differentiation compared with other tumours supporting this hypothesis.

Materials and methods
=====================

Sample information
------------------

Tumour samples were obtained from the Children\'s Cancer and Leukaemia Group (CCLG) and the Cooperative Human Tissue Network (CHTN). Twelve snap-frozen supratentorially located CNS PNETs and one pineoblastoma were obtained. Three CNS PNETs were recurrences, one with the paired primary included in the study. Ten of the CNS PNETs and the one pineoblastoma were run on Affymetrix U133 plus 2 arrays (Affymetrix, Santa Clara, CA, USA). Ten CNS PNETs were used for qPCR analysis, eight of which were also run on the arrays.

Fifty retrospective supratentorial CNS PNETs and nine pineoblastomas were obtained as paraffin-embedded blocks following formalin fixation. Seven CNS PNETs were recurrences. For six the paired primary was also included in the study. For one patient, a tumour sample was obtained from a second surgery (1 week later). Twenty-three of the primary and seven recurrent CNS PNETs plus five primary pineoblastomas were originally analysed in a previous study ([@bib58]). In this study, an additional 19 primary and 2 recurrent CNS PNETs, plus 4 primary pineoblastomas were added to the cohort. Samples were analysed using whole sections or on a tissue microarray (TMA). For TMAs, following diagnostic pathology review representative areas of tumour tissue were selected. Three cores from each tumour were included.

Clinical information was obtained from CCLG, CHTN and local centres. Multiple Centre Research Ethics Committee (MREC, 04/MRE04/72) approval was obtained. Consent for use of tumour samples was taken in accordance with national tumour banking procedures and the Human Tissue Act. Work was conducted in premises licensed under the Human Tissue Act.

Immunohistochemistry
--------------------

Immunohistochemistry was carried out on TMAs and whole sections as described previously ([@bib56]). Slides were incubated with *β*-catenin (1 in 500, Cell Signaling Technology, Danvers, MA, USA), map2 (1 in 200, Abcam, Cambridge, UK) and synaptophysin (1 in 200, Dako, Ely, UK). *β*-Catenin data from our previous study were used in our analysis ([@bib58]). Immunohistochemistry was carried out for an additional 23 samples, 19 CNS PNET and 4 pineoblastoma, as previously described ([@bib58]). Briefly, *β*-catenin was scored as nuclear or non-nuclear. The nuclear stained samples were divided into two groups defined by the percentage of positive nuclei. Samples with \<10% of nuclei positive were labelled as 'low\' and \>10% as 'high\'. Map2 was scored as positive or negative. Positive samples were split into two groups showing high and low intensity staining. Synaptophysin was scored as positive or negative.

Overall, and progression-free, survival were investigated using the Kaplan--Meier method. The differences were estimated using the log-rank (Mantel--Cox) test. Overall survival (OS) was defined as the time between date of original diagnosis and date of death. Progression-free survival (PFS) was defined as the time between date of original diagnosis and date of first event (recurrence or death). Patients still alive at the end of the study were censored at the date of last follow-up.

RNA extraction
--------------

A small piece of tissue was prepared on a glass slide as a diagnostic smear with subsequent H&E staining. Slides were reviewed by a pathologist to determine if tumour cells were present.

Total RNA was extracted from 12 CNS PNET and 1 pineoblastoma frozen tumour samples. In all, 40--50 mg of tissue was used for extraction using the *mir*Vana miRNA Isolation kit (Invitrogen, Carlsbad, CA, USA). For cell culture experiments, RNA was extracted from harvested cells using RNA STAT60 (Amsbio, Abingdon, UK) following the manufacturer\'s instructions. After extraction, RNA was treated with DNAse (Promega, Madison, WI, USA; 12 *μ*) at 37 ^°^C for 30 min. RNA quantity and quality was measured using a Nanodrop ND1000 spectrophotometer (Nanodrop, Wilmington, DE, USA) and an Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA, USA).

Gene expression microarray analysis
-----------------------------------

RNA from 10 CNS PNETs and 1 pineoblastoma were run on Affymetrix U133 plus 2.0 arrays. Three CNS PNETs were recurrences, 1 paired, plus 1 second surgery sample. Arrays were run by the NASC Affymetrix service (National Arabidopsis Stock Centre, University of Nottingham, Nottingham, UK) according to the manufacturer\'s recommendations (Affymetrix).

Raw data were processed using the robust multiarray average algorithm using Expression Console software (Affymetrix). Hierarchical clustering was performed in Spotfire DecisionSite for Functional Genomics (TIBCO Software Inc, Palo Alto, CA, USA). Euclidean distance measure and weighted pair-group average clustering method were used. Principal component analysis (PCA) and class comparisons were performed in GeneSpringGX 11.2 (Agilent Technologies). Genes differentially expressed between subgroups were identified using a *t*-test with a Benjamini and Hochberg multiple test correction ([@bib3]). Genes with a *P*-value \<0.05 were considered significant.

Microarray data from this study are available at NCBI Gene Expression Omnibus (http:/[www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)) under the accession number GSE19404.

Quantitative PCR
----------------

cDNA synthesis was carried out using the Revertaid cDNA synthesis kit (Fermentas, St Leon-Rot, Germany) using 500 ng RNA. A control was included for each sample where reverse transcriptase was excluded from the reaction mix to test for genomic DNA contamination in subsequent PCR reactions.

PCR reactions were carried as previously described ([@bib57]). Primer sequences and annealing temperatures are displayed in [Table 1](#tbl1){ref-type="table"}. Data were normalised using GAPDH. Each cDNA sample was analysed in triplicate. Primer efficiency and precision were calculated using a standard curve. Relative expression to a calibrator sample was calculated using the Pfaffl equation ([@bib46]). For tumour samples, temporal lobe RNA (BioChain, Newark, CA, USA) was used as a calibrator.

Cell culture
------------

PFSK1 cells were obtained from the American Type Culture Collection (ATCC, Teddington, UK). Cells were cultured in standard humidified incubators at 5% CO~2~ in RPMI-1640 medium (Invitrogen) supplemented with 15% fetal bovine serum (PAA Laboratories, Pasching, Austria) and antibiotics. For experiments, cells were seeded in 24-well plates and incubated overnight. The following day cells were treated with recombinant wnt3a protein at 100 ng ml^--1^ (R&D Systems, Abingdon, UK) or vehicle (PBS, 0.1% BSA). At specified time points, cells were harvested for RNA extraction.

Immunofluorescence
------------------

Cells were seeded in chamber slides. The following day cells were treated with recombinant wnt3a protein at 100 ng ml^--1^ (R&D Systems) or vehicle (PBS, 0.1% BSA). After 24 h, cells were fixed by incubating with 4% PFA for 20 min. Immunofluorescence was carried out as previously described ([@bib59]). Briefly, after blocking in 5% normal goat serum (Invitrogen) and 0.25% Triton X-100 (Sigma-Aldrich, Poole, UK) for 1 h at room temperature, cells were incubated with mouse anti-*β*-catenin primary antibody at 4 ^°^C overnight (1 in 200, 2677 Cell Signaling Technology). For signal detection, cells were incubated with Alexa Fluor 555 goat anti-mouse secondary antibody (1 in 500, Invitrogen) at room temperature for 1 h, then mounted using Vectashield containing 4′, 6-diamidinophenylindole (Vector Laboratories, Peterborough, UK). Images were obtained using a Leica DMRM fluorescent microscope (Nikon, Digital sight-USB (H), Kingston-upon-Thames, UK) equipped with a Nikon digital camera. NIS elements software was used to capture images (Nikon).

Copy number analysis
--------------------

Previously published 100K SNP array data were used to analyse DNA copy number changes (GEO accession number GSE12370; [@bib39]). Affymetrix CEL files were imported into Genespring GX11.2 (Agilent Technologies). Tumour data were either normalised using matched constitutional DNA (available for 7 samples) or the 270 HAPMAP samples ([@bib60]). GISTIC analysis was performed using Genespring GX11.2. Regions with a *q*-value \<0.25 were deemed significant.

Results
=======

We have analysed WNT/*β*-catenin pathway status using *β*-catenin IHC for additional CNS PNETs to add to our previously published cohort ([@bib58]). Our original study contained 23 primary CNS PNETs plus 5 pineoblastomas. We have almost doubled the size of our cohort, adding 19 primary CNS PNETs and 4 pineoblastomas. We used nuclear localisation of *β*-catenin to define WNT/*β*-catenin pathway activation. Nuclear localisation was seen in 11 of the 42 primary CNS PNETs (26%), 8 displaying high staining and 3 low ([Figures 1A--C](#fig1){ref-type="fig"}). Eight CNS PNET recurrences were analysed in total (two new samples). Four displayed high and two low nuclear staining. Two pineoblastomas (22%) displayed low nuclear staining.

Clinical information was available for 33 CNS PNET samples for OS analysis and 30 samples for PFS. A significant association between *β*-catenin nuclear staining and a better OS was identified in the CNS PNET cohort (*P*=0.03). An association just below significance was found with PFS (*P*=0.063). A slightly higher significance was obtained for the CNS PNET cohort if the high nuclear group was analysed against the rest of the cohort (OS *P*=0.025, PFS *P*=0.036; [Figures 1D--G](#fig1){ref-type="fig"}). The median survival for the CNS PNETs with *β-*catenin nuclear staining was 252 months with a 5-year survival rate of 52% compared with a median survival of 24 months and a 5-year survival rate of 13% in the rest of the CNS PNETs.

The number of pineoblastomas was too low to carry out a statistical analysis of survival data. However, of the two tumours displaying low nuclear positivity for *β*-catenin, one died after 15 months but the other is alive, progression free, after 169 months. The median survival for the six pineoblastomas showing either cytoplasmic or negative *β*-catenin staining was 36 months with a 5-year survival rate of 17%, which is similar to the CNS PNETs displaying this *β*-catenin staining pattern.

To understand the biological effects of WNT/*β*-catenin pathway activation, we analysed mRNA expression array data. We initially analysed a published cohort of 33 primary CNS PNETs (GEO accession number GSE14295; [@bib30]). As *β*-catenin staining had not been carried out on this cohort we used *AXIN2* expression to define pathway activation. *AXIN2* has previously been shown to be induced by the WNT/*β*-catenin pathway ([@bib26]). Increased *AXIN2* gene expression has also been seen in WNT subgroup medulloblastomas ([@bib28]; [@bib43]). We validated our findings from this cohort using array data generated from a subset of our IHC cohort, for which we could define pathway status using *β-*catenin IHC.

Initial analysis of the published cohort of 33 primary CNS PNETs identified seven tumours with high *AXIN2* expression (signal value above 3500, [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}) and therefore with predicted pathway activation. Only three of the tumours with high *AXIN2* expression had available survival data. The median survival for these tumours was 72 months with a 5-year survival rate of 60%, compared with a median survival of 13.2 months and 5-year survival rate of 9% in the rest of the cohort (*n*=19). This suggested the tumours with WNT/*β*-catenin pathway activation had a better prognosis, in agreement with our IHC analysis.

Statistical comparison of the tumours with and without pathway activation identified 86 probes with significantly different expression ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). A number of WNT/*β*-catenin pathway genes were identified including *AXIN2, WNT3A* and *LEF1*. Analysis of the gene list using ingenuity pathway analysis revealed significant enrichment for genes involved in cellular proliferation and tissue development. Many of the genes have also been linked to cancer ([Table 2](#tbl2){ref-type="table"}).

The enrichment for genes involved in tissue development suggested this process might be affected in the tumour cells. We looked at the expression of neuronal markers using the array data. Although none were identified in the statistical comparisons, a trend for lower expression of markers of neuronal differentiation was seen in the tumours with WNT/*β*-catenin pathway activation ([Figures 2A--C](#fig2){ref-type="fig"}).

We analysed the protein expression of the neuronal markers map2 and synaptophysin by IHC. High positive staining for map2 was seen in 16 out of 33 primary CNS PNETs analysed. Low or negative staining was seen in the remaining tumours ([Figure 2D, E](#fig2){ref-type="fig"}). None of the CNS PNETs displaying high map2 staining displayed high *β*-catenin nuclear staining. Four recurrences were analysed; two displaying high and two low or negative map2 expression. The two tumours displaying high map2 expression displayed cytoplasmic *β*-catenin only. Five pineoblastomas were analysed; two displaying high and three low map2 expression. One pineoblastoma, with low map2 staining, displayed low *β*-catenin nuclear staining ([Table 3](#tbl3){ref-type="table"}).

Positive staining for synaptophysin was seen in 19 out of 39 primary CNS PNETs analysed ([Figure 2F](#fig2){ref-type="fig"}). The majority of CNS PNETs with nuclear *β*-catenin staining were negative for synaptophysin (60%). Only 4 out of 19 CNS PNETs that were positive for synaptophysin displayed nuclear staining for *β*-catenin (two high and two low nuclear staining). Three out of five recurrences displayed high synaptophysin expression, one of which also displayed high and one low *β*-catenin nuclear staining. Only one out of eight pineoblastomas was negative for synaptophysin, which was one of two tumours displaying nuclear positivity for *β*-catenin ([Table 3](#tbl3){ref-type="table"}).

To confirm the gene list identified from the expression data published by [@bib30]) was associated with WNT/*β*-catenin pathway status, we looked at the expression of these genes using mRNA expression array data, we generated from 11 tumours and we analysed it in our IHC cohort for which RNA was available. All tumours had predicted WNT/*β*-catenin pathway status from *β*-catenin IHC analysis, three with nuclear staining (active) and eight without nuclear staining (inactive). We grouped the tumours using the gene list identified from Li *et al*\'s data, using hierarchical clustering and PCA. The tumours segregated into two groups according to *β*-catenin status, confirming the gene list was associated with WNT/*β*-catenin pathway activation ([Figure 3](#fig3){ref-type="fig"}).

Interestingly, one primary and recurrent pair were analysed (CNS PNET 07 and 07R), which did not cluster together. Central nervous system PNET 07 was found in the WNT group and CNS PNET 07R in the non-WNT group. This agrees with the pathway status for the two tumours, defined by *β*-catenin IHC, with CNS PNET 07 showing nuclear staining and CNS PNET 07R only cytoplasmic. In addition, in our previous study a mutation in the *β*-catenin gene was found in CNS PNET 07 but not CNS PNET 07R ([@bib58]). These results suggest the primary and recurrent tumours were biologically different.

Four genes from the identified gene list, *LEF1*, *ZIC2*, *MSX1* and *PLXNB2*, were validated using qPCR. These genes were linked to the WNT/*β*-catenin pathway and/or CNS development. Each gene displayed a significant correlation between qPCR and array data. High expression was seen in the tumours with WNT/*β*-catenin pathway activation, in agreement with the array data ([Figure 4](#fig4){ref-type="fig"}).

To further confirm the association between the identified gene list and WNT/*β*-catenin pathway activation, the CNS PNET cell line PFSK1 was treated with recombinant wnt3a protein to activate the pathway. Without wnt3a treatment, the WNT/*β*-catenin pathway was not active in PFSK1 wells, demonstrated by cytoplasmic localisation of *β*-catenin. Nuclear localisation of *β*-catenin was only seen after treatment with wnt3a protein ([Figure 5A](#fig5){ref-type="fig"}). RT--PCR demonstrated that *AXIN2* expression was induced in wnt3a-treated cells but was not expressed in vehicle-treated cells ([Figure 5B](#fig5){ref-type="fig"}). A significant increase in expression of three genes; *MSX1*, *ZIC2* and *PLXNB2*, selected from the list associated with WNT/*β*-catenin pathway activation, was seen following wnt3a treatment. This suggests the upregulation of these genes found in CNS PNETs with WNT/*β*-catenin pathway activation was directly induced by the pathway ([Figure 5C](#fig5){ref-type="fig"}).

We compared the gene list we identified associated with WNT/*β*-catenin pathway activation in CNS PNET with previously published gene lists associated with WNT/*β*-catenin pathway subgroup medulloblastomas ([@bib28]; [@bib43]). In all, 19 out of the 86 genes on our gene list were also linked to WNT subgroup medulloblastomas ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). These included genes in the WNT pathway (*AXIN2* and *LEF1*) and genes linked to brain development (*JAG2*, *LAMA5*, *EFHD1* and *ZIC2*).

We additionally analysed CNS PNET genomic copy number data, which we have previously published ([@bib39]), to see if specific changes were associated with WNT/*β*-catenin pathway activation. A subset of the tumour samples from Miller *et al*\'s study were included in the IHC cohort analysed for *β*-catenin. [Figure 6](#fig6){ref-type="fig"} displays an overview of the copy number changes across the genome. Regions of significant gain or loss were identified using GISTIC analysis. An independent analysis was carried out for CNS PNETs with and without WNT/*β*-catenin pathway activation. Only four CNS PNETs with WNT/*β*-catenin pathway activation had available copy number data limiting the power of analysis. Copy number data were available for eight CNS PNETs without pathway activation. Very few overlapping regions of gain or loss were identified in tumours with and without pathway activation. The only overlapping regions of significant copy number change were gain of two loci on 2p and loss of one locus on 11p. Significant regions of copy number gain seen in tumours with WNT/*β*-catenin pathway activation included chromosome 2 and 12q ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Only one small region of loss on 11p was significant ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). Significant gain was seen on most chromosomes in CNS PNETs without pathway activation. This included gains along chromosomes 5, 7, 9q, 14 and 17 ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}). Copy number loss was seen on chromosomes 3p, 6p, 9p, 11p, 12q and 16q ([Supplementary Table 6](#sup1){ref-type="supplementary-material"}).

Discussion
==========

We have previously published data demonstrating a potential association between WNT/*β*-catenin pathway activation and a better prognosis in CNS PNET. However, the data did not reach significance ([@bib58]). In this study, we have almost doubled the size of our cohort, which enabled us to identify a significant link to a better prognosis. We additionally identified a gene expression signature linked to pathway activation. This included a number of genes involved in the development of the CNS suggesting pathway activation in the tumours may be disrupting this process.

Our data suggest WNT/*β*-catenin pathway status, measured by *β*-catenin IHC, could be used as a prognostic marker for CNS PNETs. The link between pathway activation and a better prognosis has also been identified in medulloblastoma ([@bib13]; [@bib14]; [@bib11]), where pathway status is now being planned to be used for disease risk stratification in forthcoming medulloblastoma clinical trials ([@bib50]; [@bib12]). If the association with survival can be confirmed in independent cohorts, pathway status may be able to be used for stratification of CNS PNETs as well. However, the prognosis for medulloblastomas with WNT/*β*-catenin pathway activation is much better than CNS PNET. The 5-year OS rate for CNS PNETs with pathway activation was 52% compared with medulloblastomas where the WNT subgroup had a 5-year OS rate of 92--95% ([@bib13]; [@bib27]). In fact, even medulloblastomas without WNT/*β*-catenin pathway activation had a better 5-year OS rate (65%) than WNT CNS PNETs ([@bib13]).

The association of WNT/*β*-catenin pathway activation with a better prognosis in both CNS PNET and medulloblastoma differs to what has been found in other types of cancer including colon, hepatocellular and breast cancer ([@bib33]; [@bib22]; [@bib4]). This might suggest pathway activation is detrimental to CNS PNET or medulloblastoma survival. However in medulloblastoma, a mouse model of WNT/*β*-catenin pathway activated tumours demonstrated that aberrant pathway activation induced tumour formation suggesting it does have a role in tumour development ([@bib17]). This may also be the case in CNS PNET. If a pathogenic role can be proven, the WNT/*β*-catenin pathway provides a potential target for future therapies that would be applicable in a quarter of CNS PNET patients.

By utilising gene expression array data published by [@bib30]), we identified an expression signature linked to WNT/*β*-catenin pathway activation. Analysing the identified gene list in our independent expression array data enabled us to confirm the gene expression signature was linked to pathway activation. A number of genes on the list are involved in CNS development suggesting pathway activation may be affecting this process in the tumours. If the normal developmental process was disrupted, preventing cells from terminally differentiating, cells would remain in a more proliferative state that could lead to tumour development.

The WNT/*β*-catenin pathway has a complex role during development of the CNS. Developmental timing alters the functional impact of pathway activation on cortical neuronal precursor cells ([@bib19]). At earlier time points in development, stabilisation of *β*-catenin results in expansion of the precursor cell population and enlargement of the cerebral cortex surface area ([@bib9]; [@bib68]). However, at later time points pathway activation results in a decreased size of cerebral cortex because of a reduced proliferative progenitor cell pool and increased apoptosis ([@bib25]). Neural precursor cells cultured *in vitro* respond differently to WNT/*β*-catenin signals depending on when, in development, the cells were isolated. Cells isolated earlier in embryonic development show an increase in proliferation in response to WNT signals ([@bib63]; [@bib24]). Whereas, in those isolated later in development, neuronal differentiation is induced ([@bib20]; [@bib42]).

If the WNT/*β*-catenin pathway was aberrantly activated in neural precursor cells during the earlier phase of embryonic development, neuronal differentiation would be inhibited and the cells would remain in a proliferative state creating more favourable conditions for tumour development. The lower level of gene and protein expression of neuronal markers we demonstrated in CNS PNETs with WNT/*β*-catenin pathway activation compared with those without suggested these tumours show little neuronal differentiation supporting this hypothesis. A similar phenotype has been seen in a mouse model of CNS PNET ([@bib40]). Tumours developed following WNT/*β*-catenin pathway activation in conjunction with Myc expression and p53 knockout. Regions of differentiation were seen in the resulting tumours, but not in cells displaying nuclear *β*-catenin. In addition, in a model of WNT subgroup medulloblastoma, WNT/*β*-catenin pathway activation inhibited neuronal differentiation of cells *in vitro* ([@bib59]).

Many of the genes that displayed significantly higher expression in the WNT/*β*-catenin pathway activated tumours encode for proteins with a function in CNS development. *MSX1* is a homeobox gene, which is expressed in many different tissues during development including the CNS, where it has a role in neural tube development and inhibition of neuronal differentiation ([@bib34]; [@bib53]). Upregulated expression has been demonstrated after WNT/*β*-catenin pathway activation, including in development and cancer ([@bib65]; [@bib53]; [@bib38]; [@bib55]). *ZIC2* is a member of a family of zinc-finger transcription factors, which are involved in early neuronal development and may be involved in maintaining cell pluripotency ([@bib64]; [@bib5]; [@bib37]). *ZIC2* was downregulated in medulloblastoma compared with normal cerebellum ([@bib48]). However, upregulated expression of **ZIC2** was found in meningioma ([@bib2]). PLXNB2 is a member of the plexin family of proteins, which have a role in axon guidance ([@bib45]). It is expressed in the CNS during embryonic development and has been shown to be expressed by neuroepithelial cells at stages critical in their development ([@bib66]).

A number of the genes that we identified as linked to WNT/*β*-catenin pathway activation in CNS PNET have also been identified in WNT subgroup medulloblastomas ([@bib28]; [@bib43]), suggesting these genes maybe important to both tumour types. Overlapping genes included some which function in CNS development. *JAG2* is a member of the NOTCH pathway, which is known to have important roles during the development of the CNS. NOTCH signalling has been shown to maintain cells in a progenitor state, inhibiting differentiation ([@bib10]; [@bib67]). *LAMA*5 encodes for the alpha chain of the extracellular matrix protein laminin 5. Laminins mediate attachment, migration and organisation of cells into tissue during development including development of the CNS ([@bib32]). *EFHD1* has been shown to display increased expression during neuronal differentiation ([@bib62]).

Genes involved in embryonic development, many of which have a neuronal-specific function, were also included in the list that did not overlap with genes showing upregulation in WNT subgroup medulloblastoma, including *MSX1* and *PLXNB2. WNT3A* forms part of the WNT/*β*-catenin pathway, which is involved in the control of CNS development. In particular, *WNT3A* has been shown to be involved in promotion of the expansion of hippocampus progenitor cells ([@bib29]). *TLX1* is involved in neuronal fate specification ([@bib7], [@bib8]; [@bib18]), *KCTD11* is a marker and regulator of neuronal differentiation ([@bib15]) and *PCP4L1* is expressed in the developing brain including the cerebral cortex ([@bib6]).

Through analysis of genomic copy number data from an overlapping cohort of tumours, we were able to identify specific changes significantly enriched for in WNT/*β*-catenin pathway active or inactive CNS PNETs. The number of tumours analysed was relatively low limiting the power of the results. However, very few regions identified overlapped between CNS PNETs with or without pathway activation. Interestingly, a number of the regions identified in the WNT inactive group were previously found by Miller *et al* (2011). We used a subset of the data from this study in our analysis. Miller *et al* (2011). identified significant gain of 5q31.3, which we found to be associated with non-WNT tumours. This region contains genes from the protocadherin gamma family, which have a role in neuronal development ([@bib1]). Miller *et al* (2011) also identified loss at 9p21.3 and 3p14.2, which we found to be associated with non-WNT tumours in our analysis. The locus lost on 9p21.3 contains the tumour suppressors *CDKN2A* and *B*. In medulloblastoma, WNT active tumours have been associated with chromosome 6 monosomy ([@bib12]). We did not find this association in CNS PNET.

A recent array-based study of CNS PNETs identified three molecular subgroups ([@bib49]). A proportion of the tumours from Li *et al*\'s study, which we analysed, were included in the study by Picard *et al.* Three out of four tumours that we defined as having WNT/*β*-catenin pathway activation were found in group 3. Only 3 out of 17 tumours we defined as having no pathway activation were found in group 3. This suggests CNS PNETs with WNT/*β*-catenin pathway activation have a biological profile similar to group 3 tumours. The gene expression and clinical profile of group 3 tumours supports this conclusion. *MSX1* and *ZIC2* both displayed significantly higher gene expression in group 3 tumours. They also displayed downregulation of neural differentiation genes. Genes from the WNT pathway were significantly enriched in group 3 tumours. Group 2 tumours displayed downregulation of the WNT/*β*-catenin pathway and group 1 tumours displayed upregulation of the non-canonical WNT pathway. In addition, group 3 tumours had a better prognosis than other CNS PNETs.

Picard *et al* also linked genomic copy number changes to the CNS PNET subgroups they identified. 9p21.3 loss, which we saw in non-WNT tumours, was seen in groups 2 and 3. 8p gain, which we saw in non-WNT tumours, was seen by Picard *et al* in group 2 tumours. Interestingly, Picard *et al* found chromosome 2 gain to be associated with group 1 tumours. We found chromosome 2 gain to be associated with WNT active tumours, which does not fit with the expression profile of WNT active tumours, which was closer to group 3 tumours. However, gain of chromosome 2 was seen by Picard *et al* in some group 3 tumours. In addition, we were only able to analyse a small number of tumours limiting the power of analysis and the conclusions we could make.

Pineoblastomas were included in our analysis. These tumours resemble CNS PNETs histologically and are treated on similar protocols ([@bib51]; [@bib35]). We found two out of nine pineoblastomas displayed WNT/*β*-catenin pathway activation. Very little is known about the pathogenesis of pineoblastomas. Therefore, our results add valuable information and understanding of their underlying tumour biology.

In conclusion, we have demonstrated a significant link between WNT/*β*-catenin pathway activation and a better prognosis in CNS PNET suggesting it is a potential prognostic marker, which could be used to stratify patient disease risk. We have identified an expression signature linked to pathway activation, which contains genes involved in the control of CNS development suggesting aberrant pathway activation in the tumours maybe disrupting this process. If differentiation of progenitor cells is inhibited, cells will remain in a proliferative state creating more favourable conditions for tumour development.
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![*β*-Catenin immunohistochemistry displayed different patterns of staining in different tumours; cytoplasmic (**A**), low nuclear (\<10% nuclei) (**B**) or high nuclear (\>10% nuclei) (**C**).\
A significant association was seen between WNT/*β*-catenin pathway activation and a better OS for CNS PNETs (**D**---OS *P*=0.030). An association just below significance was seen for PFS (**E**---PFS *P*=0.063). Pathway activation was predicted by *β*-catenin nuclear staining (N) compared with cytoplasmic or negative staining (C/O). A significant association was also found with OS and PFS when the CNS PNETs displaying high nuclear staining (N high) were compared with the rest of the CNS PNET cohort (Rest) (**F**---OS *P*=0.025, **G**---PFS *P*=0.036).](bjc2013170f1){#fig1}

![Tumours predicted to have WNT/*β*-catenin pathway activation displayed a lower gene expression level of the neuronal markers *synaptophysin*\
(**A**), *MAP2* (**B**) and *β*-tubullin III (**C**). Expression data were taken from the array data published by [@bib30] (GEO accession number GSE14295). 16 out of 33 CNS PNETs displayed high map2 protein expression (**D**). The remaining tumours displayed low or negative staining (**E**). 19 out of 39 CNS PNETs also displayed positive protein staining for synaptophysin (**F**).](bjc2013170f2){#fig2}

![Heat map of hierarchical clustering of an independent cohort of tumours confirmed the identified gene list was associated with WNT/*β*-catenin pathway status (**A**).\
The gene list identified from the statistical analysis of the expression data published by [@bib30] (defined by AXIN2 expression) was used to cluster mRNA expression array data generated from an independent cohort of 11 tumours. The WNT/*β*-catenin pathway status of these 11 tumours was predicted from *β*-catenin IHC. The tumours segregated into two groups, represented by the dendogram along the x axis. All the tumours displaying nuclear *β*-catenin staining (red boxes) were found in one cluster group. The dendogram along the y axis represents the clustering of the genes used in the analysis. The same tumour groups found using hierarchical clustering were also identified using PCA (**B**). The percentage that each principal component contributed to the overall variation is displayed at the end of the three axis. Samples with WNT/*β*-catenin pathway activation are highlighted in red and those without in blue. The red and blue circles highlight the two groups found in the hierarchical clustering, which also segregated together in the PCA analysis, particularly along x axis, representing principal component 1, which accounted for 50.63% of the overall variation in the data set. Samples are labelled as CNS PNET and PB (pineoblastoma) followed by a number, which represents an individual patient. An R indicates a recurrent sample. Primary and recurrent samples with the same case number indicate samples from the same patient.](bjc2013170f3){#fig3}

![qPCR validation of selected genes; *LEF1* (**A**), *ZIC2* (**B**), *MSX1* (**C**) and *PLXNB2*\
(**D**). All displayed a significant correlation with mRNA expression array data (LEF1 *r*=0.701, *P*=0.05; ZIC2 *r*=0.775, *P*=0.02; MSX1 *r*=0.822, *P*=0.01; PLXNB2 *r*=0.714, *P*=0.05). A difference between tumours with and without WNT/*β*-catenin pathway activation (defined using *β*-catenin IHC) was seen for each gene.](bjc2013170f4){#fig4}

![WNT/*β*-catenin pathway activation was induced in PFSK1 cells by treatment with wnt3a recombinant protein (100 ng ml^--1^).\
After 24-h pathway activation was seen in the treated cells as indicated by nuclear localisation of *β*-catenin (**A**), measured by immunofluorescence, and induction of AXIN2 expression (**B**), measured by RT--PCR. A significant increase in expression of *MSX1, ZIC2* and *PLXNB2* was seen after 24 h, measured by qPCR. For *ZIC2*, a higher increase in expression was seen after 48 h (**C**). Expression in the wnt3a-treated cells is shown relative to the vehicle-treated cells. \**P*\<0.05, \*\**P*\<0.01.](bjc2013170f5){#fig5}

![Heatmap visualisation of genome-wide copy number data for 12 primary CNS PNETs with or without WNT/*β*-catenin pathway activation.\
Pathway activation was determined by *β*-catenin IHC where nuclear localisation represented pathway activation. Copy number data were generated using Affymetrix 100K SNP arrays. Each column represents a tumour sample.](bjc2013170f6){#fig6}

###### Primer sequences

  **Gene name**   **Forward primer sequence (5′--3′)**   **Reverse primer sequence (5′--3′)**   **Annealing temperature**
  --------------- -------------------------------------- -------------------------------------- ---------------------------
  *LEF1*          AAGCCCAGCACTTGAATTGT                   ATGACAGTTTTGGGCAAAGG                   62 ^°^C
  *ZIC2*          CTAATCTCCATGCCCACGTT                   GAACGCAATCCGGAGTTTTA                   59 ^°^C
  *MSX1*          GAACGCAATCCGGAGTTTTA                   CAGGAGACATGGCCTCTAGC                   63 ^°^C
  *PLXNB2*        TACGATGCCTTCCTGACCTC                   TCTTGGAACTGCTCCCAGTC                   61 ^°^C
  *AXIN2*         TGCTTTCGTGGAAATGACAG                   AGGTGTGTGGAGGAAAGGTG                   61 ^°^C
  *GAPDH*         ATGTTCGTCATGGGTGTGAA                   GTCTTCTGGGTGGCAGTGAT                   59--63 ^°^C

###### Summary of the top biological functions identified from IPA for the genes displaying a significant difference in expression between CNS PNETs predicted to have WNT/*β*-catenin pathway activation and the rest of the cohort

  **Name**                                             ***P*****-value**   **Number of molecules**
  --------------------------------------------------- ------------------- -------------------------
  **Diseases and disorders**                                              
  Dental disease                                       1.10E-03-1.65E-02              2
  Antimicrobial disease                                3.32E-03-3.32E-03              1
  Cancer                                               3.32E-03-4.67E-02             20
  Cardiovascular disease                               3.32E-03-9.92E-03              2
  Developmental disorder                               3.32E-03-4.55E-02              6
  **Molecular and cellular functions**                                    
  Cell cycle                                           1.08E-05-2.95E-02              5
  Cellular compromise                                  2.99E-04-3.59E-02              5
  Cellular development                                 4.78E-04-4.75E-02             18
  Cellular growth and proliferation                    9.59E-04-4.87E-02             17
  Cell morphology                                      1.98E-03-4.23E-02              4
  **Physiological system development and function**                       
  Digestive system development and function            1.22E-06-2.62E-02              6
  Organ development                                    1.22E-06-3.27E-02              8
  Haematological system development and function       1.08E-05-4.23E-02              5
  Humoral immune response                              1.08E-05-9.59E-04              2
  Tissue development                                   8.83E-05-4.59E-02             11

Abbreviations: CNS PNET=central nervous system primitive neuroectodermal tumour; IPA=ingenuity pathway analysis.

###### Immunohistochemistry results for *β*-catenin, map2 and synaptophysin analysed on CNS PNET and pineoblastoma cohorts

  **Tumour type**   **Primary/recurrence**   *β***-Catenin**   **MAP2**        **Synaptophysin**
  ----------------- ------------------------ ----------------- --------------- -------------------
  CNS PNET          Primary                  Negative          Negative        Negative
  CNS PNET          Primary                  Negative          High positive   Positive
  CNS PNET          Primary                  Negative          High positive   Negative
  CNS PNET          Primary                  Negative                          Positive
  CNS PNET          Primary                  Negative                          Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Negative
  CNS PNET          Primary                  Cytoplasmic       Negative        Negative
  CNS PNET          Primary                  Cytoplasmic       Low positive    Positive
  CNS PNET          Primary                  Cytoplasmic       Low positive    Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Positive
  CNS PNET          Primary                  Cytoplasmic       Low positive    Negative
  CNS PNET          Primary                  Cytoplasmic       High positive   Negative
  CNS PNET          Primary                  Cytoplasmic       Low positive    Negative
  CNS PNET          Primary                  Cytoplasmic       High positive   Negative
  CNS PNET          Primary                  Cytoplasmic       Negative        Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Negative
  CNS PNET          Primary                  Cytoplasmic       High positive   Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Positive
  CNS PNET          Primary                  Cytoplasmic       Negative        Negative
  CNS PNET          Primary                  Cytoplasmic       Negative        Positive
  CNS PNET          Primary                  Cytoplasmic       High positive   Negative
  CNS PNET          Primary                  Cytoplasmic       Low positive     
  CNS PNET          Primary                  Cytoplasmic                       Positive
  CNS PNET          Primary                  Cytoplasmic                       Positive
  CNS PNET          Primary                  Cytoplasmic                       Negative
  CNS PNET          Primary                  Cytoplasmic                       Negative
  CNS PNET          Primary                  Cytoplasmic                       Negative
  CNS PNET          Primary                  Low nuclear       Negative        Positive
  CNS PNET          Primary                  Low nuclear       High positive   Negative
  CNS PNET          Primary                  Low nuclear       High positive   Positive
  CNS PNET          Primary                  High nuclear      Negative        Negative
  CNS PNET          Primary                  High nuclear      Negative        Negative
  CNS PNET          Primary                  High nuclear      Negative        Negative
  CNS PNET          Primary                  High nuclear      Low positive    Negative
  CNS PNET          Primary                  High nuclear      Low positive    Positive
  CNS PNET          Primary                  High nuclear      Low positive    Negative
  CNS PNET          Primary                  High nuclear                      Positive
  CNS PNET          Recurrence               Cytoplasmic       High positive   Negative
  CNS PNET          Recurrence               Cytoplasmic       High positive   Positive
  CNS PNET          Recurrence               Low nuclear                       Positive
  CNS PNET          Recurrence               High nuclear      Low positive    Negative
  CNS PNET          Recurrence               High nuclear      Negative        Negative
  CNS PNET          Recurrence               High nuclear                      Positive
  Pineoblastoma     Primary                  Negative          Low positive    Positive
  Pineoblastoma     Primary                  Negative          High positive   Positive
  Pineoblastoma     Primary                  Cytoplasmic       Low positive    Positive
  Pineoblastoma     Primary                  Cytoplasmic       High positive   Positive
  Pineoblastoma     Primary                  Cytoplasmic                       Positive
  Pineoblastoma     Primary                  Cytoplasmic                       Positive
  Pineoblastoma     Primary                  Low nuclear       Low positive    Negative
  Pineoblastoma     Primary                  Low nuclear                       Positive

Abbreviation: CNS PNET=central nervous system primitive neuroectodermal tumour.
